Literature DB >> 34879703

Maternal Vascular Lesions in the Placenta Predict Vascular Impairments a Decade After Delivery.

Janet M Catov1,2, Matthew F Muldoon3, Robin E Gandley1, Judith Brands1, Alisse Hauspurg1, Carl A Hubel1, Marie Tuft4, Mandy Schmella5, Gong Tang4, W Tony Parks6.   

Abstract

Women with adverse pregnancy outcomes later experience excess hypertension and cardiovascular disease, but how the events are linked is unknown. Examination of the placenta may provide clues to vascular impairments after delivery. Maternal vascular malperfusion lesions (MVMs) were abstracted from clinical reports, validated and characterized using clinical guidelines and severity score. A total of 492 women (170 with MVMs and 322 without MVMs) participated in a study visit 8 to 10 years after delivery to assess blood pressure, cardiometabolic factors, and sublingual microvascular features using sidestream dark field imaging. Covariates included age, race, adverse pregnancy outcomes (preeclampsia, small for gestational age, and preterm birth), and health behaviors. Women with versus without MVM had a distinct sublingual microvascular profile comprised of (1) lower microvascular density (-410 μm/mm2, P=0.015), (2) higher red blood cell filling as a marker of perfusion (2%, P=0.004), and (3) smaller perfused boundary region (-0.07 µm, P=0.025) as a measure of glycocalyx integrity, adjusted for covariates including adverse pregnancy outcomes. Women with MVM also had higher adjusted diastolic blood pressure (+2.6 mm Hg, P=0.021), total and LDL (low-density lipoprotein)-cholesterol (+11.2 mg/dL, P=0.016; +8.7 mg/dL, P=0.031). MVM associations with subsequent cardiovascular measures did not vary by type of adverse pregnancy outcome, except among women with preterm births where blood pressure was higher only among those with MVM. Results were similar when evaluated as MVM severity. A decade after delivery, women with placental vascular lesions had an adverse cardiovascular profile comprised of microvascular rarefaction, higher blood pressure and more atherogenic lipids. Placental histopathology may reveal a woman's early trajectory toward subsequent vascular disease.

Entities:  

Keywords:  blood pressure; hyperlipidemias; microvascular rarefaction; placenta; pregnancy

Mesh:

Substances:

Year:  2021        PMID: 34879703      PMCID: PMC9026545          DOI: 10.1161/HYPERTENSIONAHA.121.18394

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   9.897


  61 in total

1.  Skin capillary density changes in normal pregnancy and pre-eclampsia.

Authors:  Khaled M Hasan; Isaac T Manyonda; Fu Siong Ng; Donald R Singer; Tarek F Antonios
Journal:  J Hypertens       Date:  2002-12       Impact factor: 4.844

2.  ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia.

Authors: 
Journal:  Obstet Gynecol       Date:  2019-01       Impact factor: 7.661

3.  Impaired coronary microvascular function and increased intima-media thickness in preeclampsia.

Authors:  Faika C Ciftci; Mustafa Caliskan; Ozgur Ciftci; Hakan Gullu; Ayla Uckuyu; Erzat Toprak; Filiz Yanik
Journal:  J Am Soc Hypertens       Date:  2014-08-21

4.  Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association.

Authors:  Nisha I Parikh; Juan M Gonzalez; Cheryl A M Anderson; Suzanne E Judd; Kathryn M Rexrode; Mark A Hlatky; Erica P Gunderson; Jennifer J Stuart; Dhananjay Vaidya
Journal:  Circulation       Date:  2021-03-29       Impact factor: 29.690

5.  Maternal risk of hypertension 7-15 years after pregnancy: clues from the placenta.

Authors:  C B Holzman; P Senagore; J Xu; G L Dunietz; K L Strutz; Y Tian; B L Bullen; M Eagle; J M Catov
Journal:  BJOG       Date:  2020-09-15       Impact factor: 6.531

Review 6.  Review: Preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses.

Authors:  A C Staff; R Dechend; C W G Redman
Journal:  Placenta       Date:  2012-12-13       Impact factor: 3.481

7.  Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability.

Authors:  Max Nieuwdorp; Marijn C Meuwese; Hans L Mooij; Can Ince; Lysette N Broekhuizen; John J P Kastelein; Erik S G Stroes; Hans Vink
Journal:  J Appl Physiol (1985)       Date:  2007-12-27

8.  Increase in perfused boundary region of endothelial glycocalyx is associated with higher prevalence of ischemic heart disease and lesions of microcirculation and vascular wall.

Authors:  Alexander Y Gorshkov; Marina V Klimushina; Sergei A Boytsov; Alexander Y Kots; Nadezhda G Gumanova
Journal:  Microcirculation       Date:  2018-05       Impact factor: 2.628

9.  Placental findings in non-hypertensive term pregnancies and association with future adverse pregnancy outcomes: a cohort study.

Authors:  Alisse Hauspurg; Emily K Redman; Vanessa Assibey-Mensah; W Tony Parks; Arun Jeyabalan; James M Roberts; Janet M Catov
Journal:  Placenta       Date:  2018-12-21       Impact factor: 3.481

10.  Early Onset Preeclampsia Is Associated With Glycocalyx Degradation and Reduced Microvascular Perfusion.

Authors:  Tracey L Weissgerber; Oscar Garcia-Valencia; Natasa M Milic; Elizabeth Codsi; Hajrunisa Cubro; Meryl C Nath; Wendy M White; Karl A Nath; Vesna D Garovic
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

View more
  2 in total

1.  Associations between parental type 2 diabetes risk and offspring birthweight and placental weight: a survival analysis using the Walker cohort.

Authors:  Carlos Sánchez-Soriano; Ewan R Pearson; Rebecca M Reynolds
Journal:  Diabetologia       Date:  2022-08-11       Impact factor: 10.460

2.  Placental Pathology as a Tool to Identify Women for Postpartum Cardiovascular Risk Screening following Preeclampsia: A Preliminary Investigation.

Authors:  Samantha J Benton; Erika E Mery; David Grynspan; Laura M Gaudet; Graeme N Smith; Shannon A Bainbridge
Journal:  J Clin Med       Date:  2022-03-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.